OrbiMed

OrbiMed is a healthcare-dedicated investment firm, with approximately $5 billion in assets under management. OrbiMed's investment advisory business was founded in 1989 with a vision to invest across the spectrum of healthcare companies: from private start-ups to large multinational companies. OrbiMed manages the Caduceus Private Investments series of venture capital funds and a family of public equity investment funds.
RA

Roy Amariglio

Principal

Mona Ashiya

Partner

David Bonita

General Partner

Sven Borho

Managing Partner

Vince Burgess

Venture Partner

EC

Evan Caplan

Principal

Erez Chimovits

Partner

Nissim Darvish

Venture Partner

RG

Ronny Ginor

Venture Partner

Carl Gordon

Managing Partner

Rishi Gupta

Partner

Geoffrey Hsu

General Partner

Samuel Isaly

Managing Partner

Mark Jelley

Partner

Chau Khuong

Partner

Kevin Koch

Venture Partner

Anat Naschitz

Venture Partner

Carter Neild

Managing Partner

Trevor Polischuk

Partner

Matthew Rizzo

General Partner

William F. Sawyer

Partner

Sunny Sharma

Partner

Michael B. Sheffery

Partner and Co-Founder

Jonathan Silverstein

Partner

Stephen Squinto

Partner

C. Scotland Stevens

General Partner

Kerrie Swingle

Director of Investor Services

Peter Thompson

General Partner

Klaus Veitinger

Venture Partner

Jonathan Wang

Senior MD

David Wang

Partner

Steven D. Wang

Partner

TZ

Tal Zaks

Partner

571 past transactions

Acceleron Pharma

Series C in 2007
Biopharmaceutical company engaged in developing, manufacturing and commercializing novel biotherapeutics

MDClone

Series B in 2019
MDClone Ltd. designs and develops software that analyzes medical records. Its software platform creates synthetic medical records for fictitious patients, avoiding the risk of public disclosure of actual medical data. The company’s platform enables researchers to examine the behavior of the disease, doctors, drugs, and health organizations without risking private patient medical data. MDClone Ltd. was founded in 2016 and is based in Beersheba, Israel.
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers. Its lead product candidate is ORIC-101, a small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeutics across various solid tumors. The company’s second product candidate is ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. It is also developing multiple precision medicines targeting other cancer resistance mechanisms. The company was founded in 2014 and is headquartered in South San Francisco, California.

PMV Pharmaceutcals

Series A in 2014
PMV Pharma is developing first-in-class p53 and p53 pathway modulators for the treatment of cancer. Bringing together leaders in the field to utilize over three decades of p53 biology, PMV Pharma combines unique biological understanding with pharmaceutical development focus.
Shenzhen Dami He Xiaomi Cultural Broadcast Co., Ltd., doing business as Dami & Xiaomi, operates an online platform for children with autism spectrum. Its platform provides integrated services, such as rehabilitation, education support, parent training, online courses, and science information. The company was founded in 2014 and is based in Shenzhen, China.

SI-BONE, Inc.

Venture Round in 2014
SI-BONE, Inc., a medical device company, develops implantable devices used in the surgical treatment of the sacropelvic anatomy in the United States and Internationally. The company offers iFuse, a minimally invasive surgical implant system, which is intended to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that causes lower back pain. SI-BONE, Inc. was founded in 2008 and is headquartered in Santa Clara, California.

Predix Pharmaceuticals

Venture Round in 2001
Predix is a drug discovery and development company that uses a novel 3D Discovery and Optimization Engine for GPCR drug candidates and is taking its novel compounds into the clinic. The discovery engine uses a sophisticated proprietary algorithm, PREDICT(TM), for computer modeling the 3D structure of any GPCR target; advanced technologies HYPERION(TM) and RISS(TM) for rapid high-throughput in silico screening of millions of compounds against the 3D in silico model of the target; and an integrated medicinal/computational platform for lead optimization based on the receptor's structure (ICELR-3D(TM)) and predictive algorithms for important drug properties. In August, Predix and Physiome Sciences Inc. combined companies and expanded the expertise into ion channel drug discovery.

Vivimed Labs

Post in 2018
Vivimed Labs has metamorphosed from a domestic small, entrepreneurial family-operated business to a globally renowned supplier of niche molecules and formulations across Healthcare, Pharmaceuticals and Specialty Chemicals consumers in nearly 50 countries.Driven by our philosophy of using chemistry as a base to create ingredients which touch human life on a day to day basis, Vivimed Labs delivers world-class products across the various segments They serve.

MethylGene

Venture Round in 2012
MethylGene Inc. (TSX:MYG) is a publicly-traded, clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics with a focus on cancer. The Company's product candidates include: MGCD265, an oral, multi-targeted kinase inhibitor targeting the Met, VEGF, Ron and Tie-2 receptor tyrosine kinases that is in multiple clinical trials for cancer; MGCD290, a fungal Hos2 inhibitor for use in combination with fluconazole for serious fungal infections which has completed Phase I clinical studies; and mocetinostat (MGCD0103), an oral, isoform-selective HDAC inhibitor for cancer which has been in multiple Phase II clinical trials and is currently in a Phase II trial in refractory or relapsed follicular lymphoma. Mocetinostat is licensed to Taiho Pharmaceutical Co. Ltd in certain Asian countries. A fourth compound discovered using MethylGene's HDAC platform, EVP-0334 - a potential cognition enhancing agent for neurodegenerative diseases has successfully completed Phase I trials sponsored by EnVivo Pharmaceuticals Inc. MethylGene also has a funded collaboration with Otsuka Pharmaceutical Co. Ltd. for applications in ocular diseases using the Company's proprietary kinase inhibitor chemistry.

Insulet Corporation

Series E in 2006
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. Its Omnipod System comprise two devices: a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, and its wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, and the Middle East. Insulet Corporation was founded in 2000 and is headquartered in Acton, Massachusetts.

Ambit Biosciences

Venture Round in 2012
Ambit Biosciences is a privately-held biopharmaceutical company engaged in the discovery and development of small molecule kinase inhibitors for the treatment of cancer, inflammatory disease, and other indications. Ambit's lead compound, AC220, is a novel, potent, highly selective, orally bioavailable FMS-like tyrosine kinase-3 (FLT3) inhibitor, and is currently under clinical investigation in patients with relapsed or refractory AML. Ambit is developing AC220 in collaboration with Astellas Pharma Inc. as part of a worldwide agreement to jointly develop and commercialize FLT3 kinase inhibitors in oncology and non-oncology indications. In addition to AC220, Ambit's clinical pipeline includes AC480, a pan-HER inhibitor, and AC430, an oral JAK2 inhibitor. Ambit also has a pipeline of preclinical candidates which includes CEP-32496, a BRAF inhibitor licensed to Cephalon.

RayzeBio

Series C in 2021
RayzeBio, Inc. is a biotechnology company that develops tumor-targeted small molecule medicines that harness the power of radioisotopes. The company provides macrocyclic peptide mimetic binders to deliver therapeutic radioisotopes, such as Actinium-225, an alpha-emitter for solid tumors. RayzeBio, Inc. was founded in 2020 and is based in San Diego, California.

SmartZyme Innovation LTD.

Series B in 2018
Better Continuous Glucose Monitors with a Next-Generation Glucose Sensing Enzyme SmartZyme BioPharma, Inc. is a medical technology company enabling a seamless leap to better performing glucose monitoring for people with diabetes. The company is accelerating the integration of SmartZyme's next-generation glucose-sensing enzyme into continuous glucose monitoring devices. A next-generation enzyme means no more signal mediators for the most cost-effective manufacturing; no more hypoglycemic errors for a superior safety profile; and no more fingersticks for the best quality of life. SmartZyme is an OrbiMed portfolio company.
Asian Institute of Medical Sciences is a 425 bedded super specialty hospital in Delhi NCR, India which is dedicated to provide accessible, affordable and best available healthcare services in India. Accredited by NABH and NABL, Asian Hospital Faridabad provides preventive, diagnostic, therapeutic, rehabilitative, palliative and supportive services all under one roof and is designed to meet patient care and research requirements of the new millennium. Asian Institute of Medical Sciences offers comprehensive multi-specialty tertiary care facilities through its 14 centres of excellence. - ASIAN CANCER CENTRE - ASIAN CENTRE FOR BONE MARROW TRANSPLANT - ASIAN HEART CENTRE - ASIAN CENTRE FOR ADVANCED SURGERY - ASIAN CENTRE FOR NEUROLOGY AND NEUROSURGERY - ASIAN CENTRE FOR UROLOGY AND KIDNEY TRANSPLANT - ASIAN CENTRE FOR RENAL DISEASES - ASIAN CENTRE FOR BONE AND JOINTS - ASIAN CENTRE FOR ADVANCED IMAGING - ASIAN CENTRE FOR GASTROENTEROLOGY - ASIAN CENTRE FOR MOTHER AND CHILD - ASIAN CENTRE FOR BARIATRIC & METABOLIC SURGERY - ASIAN CENTRE FOR AESTHETIC SURGERY & MEDICINE - ASIAN IVF CENTRE

Prothelia

Venture Round in 2020
Prothelia is a US based private biotech company founded in 2007. Prothelia’s lead program is a novel protein therapy for the treatment of congenital muscular dystrophy type 1A, a rare disease affecting approximately 4,000 patients.
Born from the founders’ recognition that their diverse but complementary skills and experiences would enable them to successfully address challenges that others had not, the company set about solving a vexing problem: how to bring true proteomics to the world in a way that accelerates therapeutic development, dramatically improves medical diagnostics, and makes personalized and predictive medicine a reality. The extraordinary team at Nautilus represents a wide spectrum of disciplines and expertise, including protein chemists, chip designers, molecular biologists, data scientists, material scientists, biophysicists, optical engineers, microfluidics engineers, bioinformaticists, software engineers, and more. Nautilus is positioned to revolutionize proteomics, transform the way drugs are developed, and significantly improve the way human health is managed.

Carrot Fertility, Inc.

Series C in 2021
Carrot offers a fertility benefit for modern companies, focused on making fertility care easier, accessible, and more affordable. The company partners with modern companies to provide fertility coverage for the millions of employees. Through its software, Carrot helps employees to personalize a fertility plan, chat with fertility experts, order medications, and access unique content. It helps them access the care they need, such as egg freezing, in-vitro fertilization, fertility diagnoses, and more.

UNUM Therapeutics

Post in 2020
Unum Therapeutics uses proprietary T-cell engineering technology in combination with tumor-targeting antibodies to activate the body’s own immune system to fight cancer. Unum’s lead program, based on its Antibody-Coupled T-cell Receptor (ACTR) technology, is expected to enter Phase I clinical testing in the coming months to assess safety and efficacy. Unum is seeking partners interested in using the ACTR technology to arm proprietary tumor-specific antibodies with a T-cell to improve their therapeutic potential. The company is headquartered in Cambridge, MA.

Jinxin Fertility

Series F in 2019
Jinxin Fertility Group Limited provides assisted reproductive services (ARS) in China and the United States. The company primarily offers its patients with two treatment solutions, including artificial insemination, which can be performed with either husband’s sperm or a donor sperm; and IVF technology, whereby fertilization is achieved through conventional in vitro fertilization and embryo transfer or IVF with intracytoplasmic sperm injection. It also provides related services, such as nutrition guidance, Chinese medicine treatment, and psychological counseling to support the ARS. In addition, the company offers management services; medical services in the areas of gynecology, urology, and internal medicine; ambulatory surgery centre facilities services; and ancillary medical services. Jinxin Fertility Group Limited was founded in 2003 and is headquartered in Chengdu, China.

InventisBio Inc.

Series B in 2017
InventisBio is a biotech company whose product pipeline includes small molecule drug candidates for targeted therapies in lung cancer, breast cancer and gout. The company is also actively developing drugs that can be combined with other immune-oncology targeted therapies, such as PD-1 antibody, for various cancer indications. The company is co-founded by Dr. Yaolin Wang and other scientists who have previously worked at Merck and Schering-Plough, leading various drug discovery projects in oncology, metabolic and infectious disease areas.

Invitae

Series F in 2014
Invitae is a genetic information company whose mission is to bring genetic information into routine medical practice to improve the quality of healthcare for billions of people. Specializing in genetic diagnostics for hereditary disorders, Invitae is aggregating the world’s genetic tests into a single service with better quality, faster turnaround time, and a lower price than most single-gene diagnostic tests today. What’s our plan? It takes three steps: --Make genetic testing more affordable and accessible than ever before. --Build a secure and trusted genome management infrastructure. --Design a new global community for sharing genetic information to advance science and medicine. Today, we are reinventing genetic testing by lowering the barriers for clinicians and patients to obtain diagnostic genetic information. Together we can improve healthcare for billions of people.

Laxmi Dental

Venture Round in 2015
Laxmi Dental Export Private Limited operates a dental laboratory that specializes in providing dental products and services. The company manufactures prosthodontics and dental cosmetic products, such as porcelain fused to metals, restoration dental materials, ceramic restorations, implant systems, composites, and cast partial dentures. It serves laboratories and dentists worldwide. The company was incorporated in 2004 and is based in Mumbai, India.

TigerConnect, Inc.

Debt Financing in 2018
TigerConnect is a provider of clinical communication solutions, TigerConnect helps physicians, nurses, and other staff communicate and collaborate more effectively, accelerating productivity, reducing costs, and improving patient outcomes. Trusted by more than 4,000 healthcare organizations, TigerConnect maintains 99.99% uptime and processes over 10 million messages each day. Its category-leading product innovations and advanced integrations with critical hospital systems deliver high value for hospitals and large health systems. Their commitment to client success is reflected in their broad support organization that works directly with clients at every stage to streamline communication workflows and achieve the highest possible ROI. The company was incorporated in 2010 and is headquartered in Santa Monica, California.

Garuda Therapeutics

Series B in 2023
Garuda Therapeutics is developing off-the-shelf hematopoietic stem cell (HSC) therapies to treat a broad range of severe and life-threatening diseases.

Dimension Therapeutics

Series B in 2015
Dimension Therapeutics is a gene therapy company focused on developing novel treatments for rare diseases. Their team comprises biotech industry veterans and thought leaders in gene therapy and rare diseases. The company is focused on advancing its platform of gene therapy programs in rare diseases through clinical development, starting with lead programs in hemophilia, and building out a world-class product engine for adeno-associated virus (AAV) therapeutics. In conjunction with its launch, Dimension has entered into an exclusive license and collaboration with REGENX Biosciences. REGENX holds exclusive rights to a portfolio of over 100 patents and patent applications pertaining to its NAV vector technology and related applications. Through its license and collaboration with REGENX, Dimension has acquired preferred access to NAV vector technology and rights within REGENX product programs in multiple rare disease indications. Dimension has completed a Series A financing led by Fidelity Biosciences.

iECURE

Series A in 2021
iECURE is a mutation-agnostic in vivo gene editing company striving to cure devastating diseases with high unmet needs.
Owlet Baby Care Inc. develops and manufactures a monitor that tracks babies breathing and heart rate. It offers Owlet Smart Sock, a monitoring product that sends alerts to the base station when babies stop breathing while sleeping. The company’s monitor is compatible with iOS and Android devices. It sells its products online. Owlet Baby Care Inc. was founded in 2012 and is based in Lehi, Utah.

Adaptimmune

Series A in 2014
Adaptimmune develops T cell therapies to treat cancer, human immunodeficiency virus, and infectious diseases. It utilizes the T cell to target and destroys cancerous or infected cells by using affinity T cell receptor proteins as a means of strengthening patient T cell responses. The company was incorporated in 2007 and is based in Abingdon, United Kingdom.

MBX Biosciences, Inc.

Series A in 2020
MBX Biosciences is a biotechnology company that develops therapies to treat rare endocrine diseases where there is inadequate treatment available. It focuses on the discovery, development, and commercialization of first-in-class endocrine therapeutics. The company was founded in 2018 and headquartered in Carmel, Indiana.

Bellus Health

Post in 2018
BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of chronic cough and other hypersensitization disorders. Its lead drug candidate includes BLU-5937, an oral small molecule antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of chronic cough and chronic pruritus. BELLUS Health Inc. was founded in 1993 and is headquartered in Laval, Canada.

Silverback Therapeutics

Series C in 2020
Silverback Therapeutics is a biopharmaceutical company that develops ImmunoTAC therapies targeting previously inaccessible disease pathways. They developing a new generation of systemically delivered, locally active therapies that potently modulate fundamental disease pathways once deemed inaccessible. Silverback Therapeutics is building a platform technology capable of unlocking potent immuno-modulatory pathways using an established antibody-guided approach for targeting disease sites. The company's proprietary ImmunoTAC technology and integrated R&D approach enables the design of product candidates that can be administered systemically, but that act only at the sites of disease.

Alector

Series E in 2018
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in phase II clinical trial for the treatment of frontotemporal dementia disease; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer’s and Parkinson’s diseases. The company also offers AL002 and AL003, which are in phase 1b clinical trial for the treatment of Alzheimer’s disease. In addition, it has 10 programs under research and development stage. The company has a collaboration agreement with Adimab, LLC for the research and development of antibodies. Alector, Inc. was founded in 2013 and is headquartered in South San Francisco, California.

BlossomHill Therapeutics

Series A in 2021
BlossomHill Therapeutics, Inc. is a small molecule drug discovery and development company focused on unmet medical needs in oncology and autoimmune disorders.

CBT Pharmaceuticals

Series B in 2019
CBT Pharmaceuticals is an emerging life sciences oncology company focused on developing innovative medicines targeting the growth and proliferation of cancer cells for which available treatments are inadequate. Our pipeline is comprised of four development-stage assets – an oral agent that specifically targets cancer metastasis, a pre-clinical candidate that targets uncontrolled growth signaling pathways, and two investigational products that restore the body’s immune system to recognize and kill cancer cells.

Theseus Pharmaceuticals

Venture Round in 2018
Theseus Pharmaceuticals is a Technology based company.

Sonendo

Private Equity Round in 2017
Sonendo developing innovative technologies to transform dentistry by Saving Teeth Through Sound Science®. The GentleWave® System shows significant improvements in clinical efficacy and practice efficiency when compared to standard root canal treatment.1,2, 3 Sonendo is the parent company of TDO® Software, the developer of the most widely used endodontic practice management software in the world, designed to simplify practice workflow. TDO software seamlessly integrates practice management, imaging, social media, referral reporting, CBCT imaging, and offers built-in communication with the GentleWave System.

GENEWIZ, Inc.

Venture Round in 2015
GENEWIZ is a leading global genomics service company. A full-service provider, GENEWIZ provides DNA sequencing, gene synthesis, molecular biology, next generation sequencing, bioinformatics, and GLP regulatory services. From the company’s founding, GENEWIZ has maintained its unwavering commitment to providing customers with the best value. Excelling in both science and customer support, GENEWIZ is dedicated to accelerating scientific discovery, as well as to developing and delivering innovative solutions for translational medicine and healthcare. Easily accessible around the world, GENEWIZ is the preferred partner at leading academic, pharmaceutical, biotechnology, agricultural, government, and clinical institutions. At GENEWIZ, it is their mission to contribute to the advancement of life sciences and technologies. Together with their clients, they can make a difference in the pursuit of scientific discoveries, better healthcare, a greener environment, and abundant food supplies. Their goal is to be the best in the world and the best for the world. Headquartered in South Plainfield, NJ, GENEWIZ is a privately-held global enterprise with locations in Boston, MA; Washington, DC Metro; Research Triangle Park, NC; San Diego, CA; Los Angeles, CA; San Francisco, CA; and Seattle, WA. International locations include Beijing, China; Suzhou, China; London, United Kingdom; Langen, Germany; and Tokyo, Japan.

Q32 Bio

Series B in 2020
Q32 Bio is a biotechnology company developing treatments for patients with severe autoimmune and inflammatory diseases. Q32 Bio is addressing dysregulation to help patients take back control of their lives in diseases with few to no treatment options, or those diseases where current therapeutics provide inadequate relief. Q32 Bio consists of a team of scientists and industry veterans with strong expertise in immunology. The team has a strong track record of discovering and developing new and innovative therapies.
Alpine Immune Sciences is an immunotherapy startup focused on developing recombinant, protein-based therapeutic solutions. It was founded on January 23, 2015, and is based in Seattle, Washington, United States.

Ornim Medical

Series B in 2012
Ornim, Inc. develops medical monitoring tools for the measurement of blood flow and oxygen saturation in patients. The company offers CerOx, a non-invasive monitor, which provides real-time data on oximetry and blood flow measurements of specific tissue. Its products are used for applications in neurological treatments and cardiac surgery. The company was founded in 2004 and is based in Santa Clarita, California. It has a research and development subsidiary operation in Israel.

ReCode Therapeutics

Series A in 2020
Recode Therapeutics, Inc., a biopharmaceutical company, develops precision medicines for pulmonary diseases. Its pipeline includes programs for primary ciliary dyskinesia and nonsense mutations in cystic fibrosis. The company’s non-viral lipid nanoparticle platform enables the delivery of various payloads, and precise organ targeting of nucleic acid and protein payloads via both systemic and local delivery. Recode Therapeutics, Inc. was founded in 2015 and is based in Menlo Park, California.

Prevail Therapeutics

Series A in 2018
Prevail Therapeutics Inc., a gene therapy company, focuses on developing and commercializing disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases. The company’s lead product candidate is PR001, which is in Phase I/II clinical trial for the treatment of Parkinson’s disease with GBA1 mutation and neuronopathic Gaucher disease. It is also developing PR006 for the treatment of frontotemporal dementia with GRN mutation; and PR004 for the treatment of synucleinopathies. Prevail Therapeutics Inc. was founded in 2017 and is based in New York, New York.

Adicet Bio

Series A in 2016
Adicet Bio is a pre-clinical stage biotechnology company engaged in the design and development of cutting-edge allogeneic immunotherapies for cancer and other diseases.

Turnstone Biologics

Series D in 2021
Turnstone Biologics Inc., a biotechnology company, focuses on the development of viral immunotherapies to improve survival of people with cancer. Its lead candidate RIVAL-01 consists of the vaccinia virus backbone encoding three potent immunomodulators, such as Flt3 ligand, anti-CTLA-4 antibody, and IL-12 cytokine designed to work together to drive immune activity and re-program the microenvironment to be best suited for tumor eradication. The company was founded in 2015 and is based in Ottawa, Canada with an additional office in New York, New York.

Arsanis

Series A in 2011
As of March 13, 2019, Arsanis, Inc. was acquired by X4 Pharmaceuticals Inc., in a reverse merger transaction. Arsanis, Inc., a clinical-stage biopharmaceutical company, focuses on applying monoclonal antibody (mAb) immunotherapies to address infectious diseases in the United States. The company engages in the development of ASN500, a mAb that is in preclinical development targeting respiratory syncytial virus (RSV), a virus that can cause respiratory tract infections in young children and elderly, and immunocompromised patients. Its pipeline also comprises mAbs targeting various serious bacterial and viral pathogens, including Staphylococcus aureus and RSV. In addition, the company’s preclinical stage Gram-negative mAb programs include ASN300 for Klebsiella pneumoniae and ASN200 for Escherichia coli. Arsanis, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.

ChemomAb Ltd.

Series B in 2017
ChemomAb is a clinical stage biopharmaceutical company, founded in 2011. ChemomAb specializes in the development of proprietary monoclonal antibodies, directed towards novel targets, for the treatment of immune-mediated and fibrotic disorders including orphan indications. The leading compound, CM-101, was selected after meticulous testing in a series of pre-clinical animal models simulating human disorders and has shown promising safety and efficacy as well as a novel mechanism of action.

Atox Bio Inc.

Series F in 2017
Atox Bio is a biotechnology company that specializes in infectious diseases, immunomodulators, and critical care.It focuses on novel modulators of the immune response that target key multiple and interrelated pathways of both the adaptive and innate immune response that play critical roles in infectious and inflammatory diseases as well as ischemia/reperfusion injuries. The company was founded in 2003 and headquartered in HaMerkaz, Israel.

Agensys

Series C in 2002
Agensys a biotechnology company, engages in the research and development of therapeutic human monoclonal antibodies and antibody drug conjugates for the treatment of cancer. It offers products to treat various tumors, as well as prostate, pancreatic, and bladder cancers. The company, formerly known as UroGenesys, was founded in 1997 and is based in Santa Monica, California. As of December 18, 2007, Agensys, Inc. operates as a subsidiary of Astellas Pharma US, Inc.

Disc Medicine, Inc.

Series B in 2021
Disc Medicine is led by an experienced team of scientists and industry experts, and supported by a panel of advisors with a strong track record of discovering and developing new and innovative therapies. Disc Medicine was founded by Atlas Venture and Brian MacDonald, with Novo Ventures and Access Biotechnology joining as additional investors.

Splisense

Series B in 2021
Splisense is develops antisense oligonucleotide based therapies to target genetic diseases caused by splicing mutations. The company has developed a compound to cure the lung disease in cystic fibrosis patients carrying a specific splicing mutation. It is also developing a targeted modulation approach to correct the splicing pattern of CFTR transcripts according to the specific mutation carried.

Crossover Health

Series D in 2021
Crossover Health, Inc. provides workplace healthcare services for employers and employees in companies. It offers primary, ancillary, and advanced services, including urgent care, preventive care, chronic disease management, health risk assessment, health education, health coaching, biometrics, physical therapy, chiropractic, acupuncture, specialist preferred network, care coordination, health analytics, and remote care. The company was founded in 2010 and is headquartered in Aliso Viejo, California with health centers in Silicon Valley, as well as in other locations in the United States.

Synthorx, Inc.

Series C in 2018
Synthorx, Inc., a biopharmaceutical company, focuses on the development of cytokine Synthorin programs for the treatment of cancer and autoimmune disorders in the United States. The company's lead product candidate is THOR-707, a variant of recombinant human IL-2 that is in the development in various solid tumor types as a single agent and in combination with an immune checkpoint inhibitor. It also develops IL-2 Synthorin for autoimmune indications; IL-10 Synthorin, a naturally occurring immune cell growth factor in humans for the treatment of immuno-oncology (IO); and IL-15 Synthorins, an immunoregulatory cytokine to treat IO. In addition, the company develops other Synthorin programs targeting undisclosed cytokines that play critical roles in the orchestration of anti-tumor responses by innate and adaptive immune cells. The company was formerly known as Alinos, Inc. and changed its name to Synthorx, Inc. in March 2014. Synthorx, Inc. was founded in 2014 and is headquartered in La Jolla, California. As of January 23, 2020, Synthorx, Inc. operates as a subsidiary of Sanofi.

ViewRay, Inc.

Series C in 2010
ViewRay, Inc. designs, manufactures, and markets radiation therapy systems. The company offers MRIdian, a magnetic resonance image guided radiation therapy system to image and treat cancer patients. Its MRIdian integrates MRI technology, radiation delivery, and proprietary software to see the soft tissues, shape the dose to accommodate for changes in anatomy, and strike the target using real-time targeting throughout the treatment. The company serves university research and teaching hospitals, community hospitals, private practices, government institutions, and freestanding cancer centers. ViewRay, Inc. markets its MRIdian through a direct sales force and distribution network. It has operations in the United States, France, Germany, and internationally. The company was founded in 2004 and is headquartered in Oakwood, Ohio.

Nabriva Therapeutics plc

Series B in 2015
Nabriva Therapeutics AG operates as a biopharmaceutical company that engages in the discovery and development of antibiotics for use in community and hospital infections. The company focuses on antibiotic classes, such as pleuromutilins designed for oral and topical application; and injectable broad-spectrum anti-MRSA cephalosporins. Its products include Oral Pleuromutilins BC-3205 and BC-3781 for multi-drug resistant (MDR) pathogens, including methicillin resistant Staphylococcus aureus (MRSA), MDR Streptococcus pneumonia, and vancomycin resistant Enterococcus faecium; Topical Pleuromutilin BC-7013 for the treatment of various bacterial associated, or derived dermatological diseases; and Cephalosporins for the treatment of hospital infections. The company was formerly known as Antibiotic Research Institute and changed its name to Nabriva Therapeutics AG in February, 2006. Nabriva Therapeutics AG was founded in 2001 is based in Vienna, Austria.
Amarin Corporation is a clinical-stage biopharmaceutical company focused on improving the treatment of cardiovascular disease. Amarin’s lead candidate, AMR101, is currently being studied in two concurrently run pivotal Phase 3 trials. These trials are investigating the efficacy of AMR101 in lowering triglycerides in patients with very high triglycerides (>500mg/dl) and in patients with mixed dyslipidemia who are taking statins. Amarin’s cardiovascular programs capitalize on Amarin's expertise in the field of lipid science and the known therapeutic benefits of essential fatty acids in treating cardiovascular disease. Amarin is headquartered in Dublin, Ireland, and has its research and development headquartered in Mystic Connecticut, USA. Amarin is listed in the U.S. on NASDAQ (ticker: AMRN)

Magenta Medical LTD

Venture Round in 2023
Founded in October, 2012, Magenta Medical Ltd. is a privately held company that is engaged in the development of novel device solutions for the treatment of acute and chronic heart failure.

Achilles Therapeutics

Series C in 2020
Achilles Therapeutics is a developer of immunotherapies intended to offer next-generation, patient-specific therapies to treat cancer. The company's immunotherapies harness the immune system to destroy cancer cells that target truncal tumor neo-antigens and flags to the immune system present on the surface of every cancer cell, enabling scientists to target and destroy tumors without harming healthy tissues.
Æglea BioTherapeutics is a biotherapeutic company exploiting the amino acid (AA) dependencies of many tumors by developing novel, human-derived AA-degrading enzymes that have been engineered to have optimized catalytic and biopharmaceutic properties. The metabolic basis of tumor amino acid dependence is fundamentally different from the nutritional needs of normal tissues, creating a vulnerability to selective killing for tumor cells. The company was founded in 2013 and is headquartered in Austin, Texas.

Otic Pharma

Series B in 2012
Otic Pharma is a clinical-stage pharmaceutical company focusing on the development and commercialization of products for disorders of the ear, nose, and throat (ENT). The company has two platform technologies, each of which has the potential to be developed for multiple ENT indications. The company is currently developing a nasally-administered, combination drug product (OP-02) intended to address the underlying cause of otitis media and Eustachian tube dysfunction (OM/ETD), a condition that affects more than 700 million people around the world every year. Otitis media is one of the most common disease seen in pediatric practice and the most frequent reason children consume antibiotics or undergo surgery. The company also has a foam-based drug delivery technology platform (OP-01) that can be used to deliver drugs into the ear, nose, and sinus cavities. The company is currently developing OP-01 as an improved treatment option for acute otitis externa (“swimmers ear”). For more information on the company, please visit www.oticpharma.com

Predix Pharmaceuticals

Series A in 2000
Predix is a drug discovery and development company that uses a novel 3D Discovery and Optimization Engine for GPCR drug candidates and is taking its novel compounds into the clinic. The discovery engine uses a sophisticated proprietary algorithm, PREDICT(TM), for computer modeling the 3D structure of any GPCR target; advanced technologies HYPERION(TM) and RISS(TM) for rapid high-throughput in silico screening of millions of compounds against the 3D in silico model of the target; and an integrated medicinal/computational platform for lead optimization based on the receptor's structure (ICELR-3D(TM)) and predictive algorithms for important drug properties. In August, Predix and Physiome Sciences Inc. combined companies and expanded the expertise into ion channel drug discovery.

Enobia Pharma

Series B in 2007
Enobia develops therapies to treat serious genetic bone disorders for which there are no approved treatments.

Cyrus Biotechnology

Series B in 2021
Cyrus Biotechnology builds software tools to accelerate basic research in biotech, pharma, and industrial biotechnology. Cyrus Bench delivers an enterprise version of the Rosetta molecular modeling and design toolkit, with the associated array of bio-molecular computation tools. It was founded in 2014 and headquartered in Seattle, Washington.

Nutrinia Ltd.

Series C in 2014
Nutrinia is a neonatology company developing pharmaceuticals to treat rare conditions of the gastrointestinal tract. Our current products in development are oral formulations of insulin shown to enhance adaptation and rehabilitation of the gut in infants. We at Nutrinia live by the belief that science is best used to make life better for people, especially the most vulnerable populations.

Biodel

Post in 2011
Biodel Inc. (Biodel) is a development-stage company. The Company is a biopharmaceutical company focused on the development and commercialization of treatments for diabetes. It develops its product candidates by applying its formulation technologies to existing drugs. Its product candidate is Linjeta. It has formulated Linjeta as rapid-acting mealtime insulin for the treatment of patients with Type I and Type II diabetes. Earlier stage product candidates include follow-on and second generation rapid-acting mealtime insulins or insulin analogs, VIAtab, a sublingual tablet formulation of insulin, a line of basal insulins, and a formulation of glucagon.

Gemini Therapeutics

Series A in 2017
Gemini Therapeutics is a precision medicine company focused on genetically-defined dry age-related macular degeneration (AMD) and associated rare genetic diseases.Their therapeutic candidates are matched to molecular abnormalities found in patients with high clinical need and our broad multimodal pipeline includes monoclonal antibodies, recombinant proteins and gene therapies. Launched with funding from leading life science investors and powered by academic partnerships around the world,they are developing a series of potentially first-in-class therapeutics.
Puma Biotechnology, Inc., is a development stage biopharmaceutical company that acquires and develops innovative products for the treatment of various forms of cancer. The Company focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seeks to further develop those drug candidates for commercial use. The Company is initially focused on the development of PB-272 (oral neratinib), a potent irreversible tyrosine kinase inhibitor, for the treatment of patients with HER2 positive metastatic breast cancer.

ACADIA Pharmaceuticals Inc.

Debt Financing in 2000
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia that are in Phase III clinical trials; and pimavanserin as an adjunctive treatment for major depressive disorder. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.

Alector

Series D in 2016
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in phase II clinical trial for the treatment of frontotemporal dementia disease; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer’s and Parkinson’s diseases. The company also offers AL002 and AL003, which are in phase 1b clinical trial for the treatment of Alzheimer’s disease. In addition, it has 10 programs under research and development stage. The company has a collaboration agreement with Adimab, LLC for the research and development of antibodies. Alector, Inc. was founded in 2013 and is headquartered in South San Francisco, California.

ReCode Therapeutics

Series A in 2020
ReCode Therapeutics is a development-stage biopharmaceutical company focused on the correction of the nonsense mutations that account for 1/3 of all inherited diseases, including approximately 10% of cystic fibrosis. They have combined selected tRNAs with their unique and diverse proprietary delivery platforms to create and develop first-in-class suppressor tRNA-nanoparticle therapeutics for correcting nonsense mutations. ReCode’s diverse pipeline includes lead programs for primary ciliary dyskinesia (PCD) and nonsense mutations in cystic fibrosis (CF). The company’s proprietary non-viral lipid nanoparticle platform enables the delivery of a variety of payloads, and precise organ targeting of nucleic acid and protein payloads via both systemic and local delivery. ReCode is leveraging its nanoparticle and nucleic acid technologies across multiple modalities, including mRNA-mediated protein replacement therapies, first-in-class tRNA NanoCorrectors for diseases caused by nonsense mutations, and gene editing. The company was founded in 2015 and is based in Dallas, Texas.

MacroGenics

Venture Round in 2002
MacroGenics, Inc., a biotechnology company, focuses on the development, manufacture, and commercialization of immunotherapeutics for autoimmune disorders, cancer, and infectious diseases. The company is developing immune-based products, including monoclonal antibodies; and vaccines to prevent infections in healthy individuals. The company's Fc engineering technology enables to improve antibody functions to eliminate cancer cells. It is also developing products around the Dual Activating ReTargeting technology. The company was founded in 2000 and is headquartered in Rockville, Maryland.
Innovative Spinal Technologies is a spine technology company that develops motion preservation and minimally invasive treatments for spinal disorders. Its products include AXIENT Dynamic Fixation system, a pedicle screw-based motion system, PARAMOUNT Lumbar Fusion System, which is engineered for lumbar fusion procedures conducted in a minimally invasive, mini-open, or open fashion, PARAMOUNT MIS Pedicle Screw System for single and multi-level procedures, PARAMOUNT Open Pedicle Screw System, which is designed to meet the needs of minimally invasive lumbar fusion, and PARAMOUNT VBR, which is designed for a minimally invasive transforaminal approach. Innovative Spinal Technologies was founded in 2002 and is headquartered in Mansfield, Massachusetts

Alector

Series C in 2015
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in phase II clinical trial for the treatment of frontotemporal dementia disease; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer’s and Parkinson’s diseases. The company also offers AL002 and AL003, which are in phase 1b clinical trial for the treatment of Alzheimer’s disease. In addition, it has 10 programs under research and development stage. The company has a collaboration agreement with Adimab, LLC for the research and development of antibodies. Alector, Inc. was founded in 2013 and is headquartered in South San Francisco, California.

InspireMD

Post in 2023
InspireMD is an innovative medical device company focusing on the development and commercialization of its proprietary stent system technology, MGuard. The company intends to apply its technology to develop products used in interventional cardiology and other vascular procedures. InspireMD’s mission is to utilize its proprietary technology to make its products the industry standard for stents and to provide a superior solution to the key clinical issues of current stenting: embolic showers, restenosis, and late stent thrombosis. InspireMD intends to pursue applications of its innovative technology both for bare metal and drug eluting stents in coronary, carotid and peripheral artery procedures.
X4 Pharmaceuticals a clinical-stage oncology company developing best-in-class oral small molecule CXCR4 antagonists for the treatment. The company is developing two unique programs such as drug candidate, X4P-001, has clinical experience in over 70 subjects, and is advancing into Phase 1/2 trials in refractory clear cell renal cell carcinoma (ccRCC) and refractory epithelial ovarian cancer (EOC), the second program, X4P-002, is a unique series of late lead molecules that penetrate the blood-brain barrier. They will pursue early clinical development in glioblastoma multiforme (GBM), a rare form of lethal brain cancer, for the X4P-002 program. X4 Pharmaceuticals was founded in 2014 and is based in Cambridge, Massachusetts, United States.

LogicBio Therapeutics

Series B in 2017
LogicBio develops gene therapy vectors for previously incurable genetic and infectious diseases, including: hemophilia, HIV/AIDS and methylmalonic acidemia (MMA). Our proprietary technology based on the non-pathogenic Adeno-Associated Viral (AAV) vector offers superior efficiency and safety compared to all competitors on the market, and is uniquely suited for the treatment of children as well as adults.

ImmPACT Bio USA

Series B in 2022
ImmPACT Bio USA Inc. is a cell therapy company aiming to develop potent and selective engineered T-cells for the treatment of solid tumors. The Company's technology enables targeting loss-of-gene features of solid tumor cells, sparing normal, healthy tissues.

Zentera Therapeutics

Series A in 2020
Zentera Therapeutics is a biopharmaceutical company.

Adela

Series A in 2021
Adela is focused on the detection of cancer and other high-morbidity, high-mortality conditions through a routine blood test.

Scout Bio, Inc.

Series B in 2021
Scout Bio, Inc. researches and develops one-time therapies for major chronic pet health conditions using veterinary biotechnology and gene therapy. It offers therapies for anemia associated with chronic kidney disease (CKD) in cats. The company offers pet therapeutics, including small molecular drugs, protein therapies, and gene therapies. Scout Bio, Inc. was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.

Rimag

Series D in 2021
Rimag provides medical imaging service. The company engages in medical imaging center operation, relevant cloud technology development, and talent training. The company was founded in 2014 and is based in Shenzhen, China.

Laekna Therapeutics

Series B in 2019
Laekna Therapeutics Shanghai Co., Ltd. is a gene therapy company, which develops therapeutics for oncology and metabolic diseases. It develops pre-clinical discovery programs for oncology and liver diseases. It develops small molecule candidate LAE001 (previously known as CFG920) for prostate cancer. The company was founded in 2016 and is based in Shanghai, China.

Therachon

Series A in 2017
Therachon is a global biotechnology company focused on developing medicines for rare, genetic diseases that currently have no available treatments. The company’s lead pipeline candidate, TA-46, is a novel protein therapy in development for achondroplasia, the most common form of short-limbed dwarfism. Therachon is headquartered in Basel, Switzerland, with research labs in Nice, France.

Cleave Biosciences

Series B in 2016
Cleave Therapeutics develops oncology pharmaceuticals designed to target neurodengeneration and pathways used by cancer cells to grow. The company is engaged in the discovery of novel, small-molecule drugs that affect protein-degradation pathways, upon which cancer cells depend for survival, enabling patients to get cured from cancer.
Pandion Therapeutics is a biotechnology company developing bispecific antibody therapeutics to achieve localized immunomodulation at the site of disease for durable, tissue-specific treatment of patients with autoimmune and inflammatory diseases, and organ transplants. Pandion’s approach has the potential to more effectively induce and sustain response and remission in patients with many autoimmune and inflammatory conditions. They aim to shift the paradigm and create a new generation of drugs with transformative efficacy and improved safety.

Athersys

Venture Round in 2007
Athersys is a biopharmaceutical company engaged in the discovery and development of therapeutic product candidates designed to extend and improve the quality of human life. The product development portfolio of the Company includes MultiStem, a stem cell product, which is being developed as a treatment for multiple disease indications, and is being evaluated in two ongoing clinical trials, and has been authorized for use in a third clinical trial. In addition, the Company is developing pharmaceuticals to treat indications such as obesity, certain cognitive and attention disorders, and narcolepsy or other forms of excessive daytime sleepiness.
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers. Its lead product candidate is ORIC-101, a small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeutics across various solid tumors. The company’s second product candidate is ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. It is also developing multiple precision medicines targeting other cancer resistance mechanisms. The company was founded in 2014 and is headquartered in South San Francisco, California.
Mereo BioPharma Group plc, a specialty biopharmaceutical company, acquires, develops, and commercializes therapeutics for the treatment of rare and specialty diseases. Its product candidates include BPS-804, a monoclonal antibody, which is in Phase IIb clinical trial for the treatment of osteogenesis imperfecta; AZD-9668, an oral small molecule that has been completed Phase I clinical trial to treat Alpha-1 antitrypsin deficiency; BGS-649, an oral aromatase inhibitor, which is in Phase IIb clinical trial for the treatment of hypogonadal hypogonadism; and BCT-197, an oral p38 MAP kinase inhibitor that is in Phase II clinical trial to treat acute exacerbations of chronic obstructive pulmonary disease. Mereo BioPharma Group plc was founded in 2015 and is headquartered in London, the United Kingdom.

Caris Life Sciences, Inc.

Private Equity Round in 2020
Caris Molecular Intelligence revolutionizes precision medicine to provide physicians and patients with information about their health. They develop Caris Molecular Intelligence Services that does panomic molecular profiling for oncology. Caris Life Sciences was founded with a very simple but powerful purpose – to help improve the lives of as many people as possible. Through tireless efforts, breakthrough molecular science, and a passionate commitment to quality, they remain steadfastly focused on the most important part of their work – the patient. It was founded in 1996 and is based in Irving, Texas.

resTORbio

Series B in 2017
resTORbio is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for the treatment of aging-related diseases.The Company develops medicines and therapies to treat aging-related diseases and conditions such as cancer, heart disease, neurodegenerative diseases, and diabetes mellitus. resTORbio serves clients in the State of Massachusetts.

Q32 Bio

Series B in 2020
Q32 Bio is a biotechnology company developing treatments for patients with severe autoimmune and inflammatory diseases. Q32 Bio is addressing dysregulation to help patients take back control of their lives in diseases with few to no treatment options, or those diseases where current therapeutics provide inadequate relief. Q32 Bio consists of a team of scientists and industry veterans with strong expertise in immunology. The team has a strong track record of discovering and developing new and innovative therapies.

Verona Pharma

Post in 2020
Verona Pharma is a biotechnology company dedicated to discovering new drugs for the treatment of chronic respiratory diseases, such as asthma, allergic rhinitis (hay fever), chronic obstructive pulmonary disease (COPD) and cough.

Noctrix Health, Inc.

Series B in 2021
Noctrix Health, Inc. develops therapeutic wearable devices to treat chronic neurological and sleep disorders in patients. The company was founded in 2018 and is based in Menlo Park, California.

Principia Biopharma Inc.

Series A in 2012
Principia Biopharma is a private, pre-clinical stage company initially focused on the discovery and development of differentiated small molecule drugs targeting inflammatory/autoimmune diseases as well as cancer. The company expects to submit an IND for its lead program in 2013 and continues to invest in additional programs and its reversible covalent platform.

Salmedix Inc

Series C in 2005
Salmedix is an oncology drug development company with a commercial focus on the treatment of hematologic malignancies, or blood cancers. Its primary product, SDX-105, is marketed by healthcare professionals in Germany for the treatment of several types of blood cancers. Salmedix conducts Phase II clinical trials for SDX-105 in the U.S. and Canada. Its other clinical-stage product candidates, SDX-101 and SDX-102, each with significant prior human clinical experience, are also in Phase II development. Founded in 2000 by David Kabakoff, Salmedix is headquartered in San Diego, California.

Modis Therapeutics

Series A in 2018
Modis Therapeutics, Inc. develops disease modifying therapies for rare genetic diseases. The company designs and develops a therapy MT1621, which restores mitochondrial DNA replication fidelity. The company was incorporated in 2016 and is based in Oakland, California. As of September 6, 2019, Modis Therapeutics, Inc. operates as a subsidiary of Zogenix, Inc..
Compass Therapeutics is a clinical-stage biotechnology company targeting the human immune synapse with a new generation of antibody therapeutics. Compass has broadly drugged the immune system by generating epitopically diverse antibody panels to more than 40 targets across all immune cell types and is leveraging its proprietary StitchMabs and common light-chain based multispecific platforms to empirically identify combinations and multispecific with optimized activity. The company’s lead product candidate, CTX-471, is a fully human agonistic antibody of CD137, which is in a Phase 1 study in patients with inadequate responses to PD-1/PD-L1 checkpoint inhibitors. Compass is also progressing several preclinical assets including a novel class of NK cell engagers targeting NKp30 and multiple bispecific checkpoint programs. The company’s offices and labs are based in Kendall Square in Cambridge, Mass.
ADARx Pharmaceuticals is a genetic medicine company focusing on the base editing of mRNA transcripts. It discovers and develops innovative therapeutics that can utilize a family of endogenous enzymes called adenosine deaminase acting on RNA (ADAR) to precise target and correct single point mutations on an mRNA, thus the production of desired and functional protein is restored. It was founded in 2019 and is headquartered in San Diego, California.

Relypsa

Series B in 2011
Relypsa, Inc. is a privately-held, development stage biopharmaceutical company leading the discovery and development of novel non-absorbed polymeric drugs for important applications in cardiovascular and renal disease. Relypsa's lead product candidate is RLY5016, a non-absorbed potassium binder for the management of hyperkalemia. Relypsa is dedicated to discover additional product candidates through use of its proprietary polymer platform.